KRAS mutations are the most frequent genetic alterations seen in invasive mucinous adenocarcinoma (40%–62%) followed by NRG1 fusion (7%–27%; refs. 93, 94). This evidence concerns the gene KRAS and mucinous adenocarcinoma.